VELPHORO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELPHORO (VELPHORO).
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
| Metabolism | Not metabolized; acts locally in the GI tract; minimal systemic absorption. |
| Excretion | Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%). |
| Half-life | Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life). |
| Protein binding | Not applicable (minimal systemic absorption; binding to serum proteins negligible). |
| Volume of Distribution | Not applicable (minimal systemic absorption; Vd not defined). |
| Bioavailability | Not applicable (not intended for absorption; systemic bioavailability <0.1% based on limited data). |
| Onset of Action | Rapid (within 1 hour) binding to dietary phosphate in the GI tract. |
| Duration of Action | Duration of phosphate binding is limited to GI transit time (approximately 3–5 hours per meal), requiring administration with each meal. |
| Molecular Weight | 70000 |
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | Not applicable; drug is indicated for dialysis-dependent chronic kidney disease. No GFR-based dose reduction needed. |
| Liver impairment | No specific Child-Pugh dose adjustments provided in labeling; use with caution in severe hepatic impairment due to potential iron overload. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no weight-based guidelines available. |
| Geriatric use | No specific dose adjustment in elderly; monitor iron parameters and serum phosphorus as in younger adults. |
| 1st trimester | No adequate studies in pregnant women; animal studies show no risk. Use only if clearly needed. |
| 2nd trimester | No adequate studies in pregnant women; animal studies show no risk. Use only if clearly needed. |
| 3rd trimester | No adequate studies in pregnant women; animal studies show no risk. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for VELPHORO (VELPHORO).
| Placental transfer | Minimal to no placental transfer due to large polymer structure and lack of systemic absorption. |
| Breastfeeding | Not absorbed systemically; unlikely to pass into breast milk. Caution with iron deficiency in infant due to theoretical binding of iron. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to sucroferric oxyhydroxide or any componentBowel obstructionFecal impactionGastrointestinal bleedingHemochromatosis
| Precautions | Risk of iron overload, especially in patients with iron overload disorders or repeated blood transfusions; monitor iron status periodically., Potential for gastrointestinal adverse reactions such as discolored stools (harmless), constipation, nausea, and diarrhea. |
| Food/Dietary | VELPHORO should be taken with meals to bind dietary phosphate. No specific foods are contraindicated, but high-phosphate foods (e.g., dairy, nuts, colas) should be limited as part of a renal diet. The drug may reduce absorption of fat-soluble vitamins. |
Loading safety data…
| L1: Safest |
| Teratogenic Risk | Velphoro (sucroferric oxyhydroxide) is not absorbed systemically; therefore, no fetal exposure is expected. No teratogenicity or fetal harm is anticipated in any trimester. Animal studies with high doses showed no evidence of fetal harm. |
| Fetal Monitoring | Monitor serum phosphate levels to ensure efficacy; monitor serum iron, ferritin, and iron saturation if prolonged use to assess iron accumulation. No specific fetal monitoring required. |
| Fertility Effects | No evidence of impaired fertility in animal studies. No human data available; systemic absorption is minimal, so effects on fertility are unlikely. |
| Clinical Pearls | VELPHORO (sucroferric oxyhydroxide) is a non-calcium, iron-based phosphate binder. It should be taken with meals to maximize phosphate binding. Monitor serum phosphate levels; it is not intended for use in patients with iron overload syndromes. Do not chew or crush the chewable tablets; they should be chewed thoroughly or crushed and sprinkled on food. Avoid concomitant use with oral medications that have narrow therapeutic windows and require consistent absorption (e.g., thyroid hormones, quinolone antibiotics) by separating administration by at least 1 hour. |
| Patient Advice | Take VELPHORO with each meal as directed to control phosphate levels. · Chew tablets completely before swallowing; do not swallow whole. · Do not take VELPHORO if you have iron overload disorders. · Separate VELPHORO from other medications by at least 1 hour. · Common side effects include diarrhea, nausea, and vomiting. · Inform your doctor if you have difficulty swallowing or gastrointestinal issues. |